Price • Atrium Therapeutics
RNA
Atrium Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of atrial-selective gene therapies for the treatment of atrial fibrillation (AFib), the most prevalent sustained cardiac arrhythmia worldwide. The company's mission is to provide a durable, one-time treatment that restores and maintains normal sinus rhythm, addressing the limitations of current standard-of-care treatments such as anti-arrhythmic drugs and catheter ablation. Atrium's proprietary platform focuses on localized delivery of genetic material to the heart's atria. Its lead product candidate, ATR-101, is an investigational gene therapy designed to be delivered via a single administration to the epicardial surface of the atria during a minimally invasive procedure or concomitant with cardiac surgery. ATR-101 works by expressing a modified potassium channel that prolongs the atrial refractory period, thereby suppressing the electrical triggers and substrates that sustain AFib. By targeting the underlying electrophysiological mechanisms of the disease specifically within the atrial tissue, Atrium Therapeutics aims to minimize systemic side effects and improve long-term outcomes for patients suffering from paroxysmal or persistent AFib. The company is positioned at the intersection of cardiovascular medicine and advanced genetic therapeutics, seeking to fill a significant unmet need in the management of chronic heart rhythm disorders.